

The prior authorization (PA) letter on the following page is an example showing the type of information that may be required by an insurance company. Some plans may require the use of their own form, in which case, you can use this information to help ensure that your PA request is as complete as possible. Use of the information in this letter does not guarantee that the health plan will provide reimbursement for PEDMARK and is not intended to be a substitute for or to influence the independent medical judgment of the physician. The information on pages 1 and 3 does not need to be included in your letter. Any and all information submitted to any payer is solely the responsibility of the submitting healthcare provider.

### Suggestions

- Fax the Fennec HEARS™ Enrollment Form to 855-612-5160
- They will perform a benefits investigation and notify you about the patient's insurance coverage.
- Fax the completed form or PA letter to the health plan or submit via electronic methods approved by the health plan. If a PA request is denied, you generally have the option for multiple levels of appeal.
- Consider including a letter of medical necessity with your PA requests, along with any appeals that are submitted.

### Suggested Documentation to Consider

- Include the patient's name, member ID, group number, policy number, and date of birth
- Confirm that the patient's tumor is localized and non-metastatic
- Confirm that the patient is at risk for ototoxicity due to platinum based therapy
- If other options are proposed or required by the plan, explain why you have determined that they are not appropriate for your patient
- Check the plan's website for a PA form that they require
- PEDMARK Prescribing Information
- National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for Adolescent and Young Adult (AYA) Oncology - 2A Recommendation

PA requirements will often conform to the inclusion/exclusion criteria included in pivotal trials. Refer to examples of criteria that plans may require in the letter on the following page.

**Reprints available from your Fennec representative:**

- Brock PR, Maibach R, Childs M, et al. Sodium thiosulfate for protection from cisplatin-induced hearing loss. *N Engl J Med.* 2018;378(25):2376-2385. doi:10.1056/NEJMoa1801109
- Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet.* 2017;18(1):63-74. doi:10.1016/S1470-2045(16)30625-8

**Additional Resources**

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adolescent and Young Adult (AYA) Oncology V1.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org

**INDICATIONS AND USAGE**

PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use

The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

**SELECT IMPORTANT SAFETY INFORMATION**

- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate

Please see additional Important Safety Information on the last page. [Click here](#) for full Prescribing Information.

Example Prior Authorization Letter  
for PEDMARK® (sodium thiosulfate injection)

Contact Fennec HEARS for  
additional support  
855-615-7946

[Print letter on office letterhead]

[Date]  
[Plan name]  
[Plan street address]  
[Plan city, state zip code]

Re: [Patient full name]  
Date of Birth: [Patient date of birth]  
Member ID: [Patient ID number]  
Group Number: [Patient group number]  
Policy Number: [Patient policy number]

To whom it may concern:

I am submitting this letter for the prior authorization of PEDMARK® (sodium thiosulfate injection) for [patient full name] to reduce the risk of ototoxicity following cisplatin therapy for the treatment of [diagnosis] (ICD-10 code: [insert code]).

PEDMARK is the first FDA-approved treatment to reduce the risk of cisplatin-induced hearing loss in children being treated for certain cancers. It is indicated for intravenous use in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors, and is supported by two randomized clinical trials (RCTs) conducted at US oncology centers of excellence.

[Consider including the following information.]

- The patient's age
- The appropriate ICD-10 code for the type of cancer that you have diagnosed
- Confirmation that the tumor is localized and non-metastatic
- Confirmation that the patient is at risk of ototoxicity because of planned treatment with cisplatin

Enter the dose:

Enter the vials per cycle:

# of treatment cycles:

Refills:

Site of administration:

The use of PEDMARK is supported by two RCTs [reprints are available from your representative]. Please expedite this request, as the patient's first treatment with cisplatin is scheduled for [insert date]. The prior authorization decision may be faxed to [fax #] or mailed to [physician business office address]. Please also send a copy of the coverage determination decision to [patient name]. Thank you in advance for your immediate attention to and prompt review of this request.

Sincerely,

[Physician's signature]

[Physician's name, Phone number, NPI#]

Enclosures: [See checklist on previous page]

PEDMARK, for intravenous use

## INDICATIONS AND USAGE

PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

### Limitations of Use

The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

## IMPORTANT SAFETY INFORMATION

- PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.
- Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
- PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers
- Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
- Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m<sup>2</sup>.
- Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.
- The most common adverse reactions (≥25% with a difference between arms of >5% compared to cisplatin alone) in SIOPEL6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with a difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

[Click here for full Prescribing Information](#)

